338 related articles for article (PubMed ID: 26110445)
1. Duration of Antiretroviral Therapy Adherence Interruption Is Associated With Risk of Virologic Rebound as Determined by Real-Time Adherence Monitoring in Rural Uganda.
Haberer JE; Musinguzi N; Boum Y; Siedner MJ; Mocello AR; Hunt PW; Martin JN; Bangsberg DR
J Acquir Immune Defic Syndr; 2015 Dec; 70(4):386-92. PubMed ID: 26110445
[TBL] [Abstract][Full Text] [Related]
2. Duration of Viral Suppression and Risk of Rebound Viremia with First-Line Antiretroviral Therapy in Rural Uganda.
Musinguzi N; Mocello RA; Boum Y; Hunt PW; Martin JN; Haberer JE; Bangsberg DR; Siedner MJ
AIDS Behav; 2017 Jun; 21(6):1735-1740. PubMed ID: 27256394
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal assessment of associations between food insecurity, antiretroviral adherence and HIV treatment outcomes in rural Uganda.
Weiser SD; Palar K; Frongillo EA; Tsai AC; Kumbakumba E; Depee S; Hunt PW; Ragland K; Martin J; Bangsberg DR
AIDS; 2014 Jan; 28(1):115-20. PubMed ID: 23939234
[TBL] [Abstract][Full Text] [Related]
4. Younger Age Predicts Failure to Achieve Viral Suppression and Virologic Rebound Among HIV-1-Infected Persons in Serodiscordant Partnerships.
Mujugira A; Celum C; Tappero JW; Ronald A; Mugo N; Baeten JM
AIDS Res Hum Retroviruses; 2016 Feb; 32(2):148-54. PubMed ID: 26670218
[TBL] [Abstract][Full Text] [Related]
5. Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda.
Oyugi JH; Byakika-Tusiime J; Ragland K; Laeyendecker O; Mugerwa R; Kityo C; Mugyenyi P; Quinn TC; Bangsberg DR
AIDS; 2007 May; 21(8):965-71. PubMed ID: 17457090
[TBL] [Abstract][Full Text] [Related]
6. Incidences and factors associated with viral suppression or rebound among HIV patients on combination antiretroviral therapy from three counties in Kenya.
Maina EK; Mureithi H; Adan AA; Muriuki J; Lwembe RM; Bukusi EA
Int J Infect Dis; 2020 Aug; 97():151-158. PubMed ID: 32497804
[TBL] [Abstract][Full Text] [Related]
7. Viral Suppression and Retention in Care up to 5 Years After Initiation of Lifelong ART During Pregnancy (Option B+) in Rural Uganda.
Koss CA; Natureeba P; Kwarisiima D; Ogena M; Clark TD; Olwoch P; Cohan D; Okiring J; Charlebois ED; Kamya MR; Havlir DV
J Acquir Immune Defic Syndr; 2017 Mar; 74(3):279-284. PubMed ID: 27828878
[TBL] [Abstract][Full Text] [Related]
8. Successful antiretroviral therapy delivery and retention in care among asymptomatic individuals with high CD4+ T-cell counts above 350 cells/μl in rural Uganda.
Jain V; Byonanebye DM; Amanyire G; Kwarisiima D; Black D; Kabami J; Chamie G; Clark TD; Rooney JF; Charlebois ED; Kamya MR; Havlir DV;
AIDS; 2014 Sep; 28(15):2241-9. PubMed ID: 25022596
[TBL] [Abstract][Full Text] [Related]
9. Incomplete adherence among treatment-experienced adults on antiretroviral therapy in Tanzania, Uganda and Zambia.
Denison JA; Koole O; Tsui S; Menten J; Torpey K; van Praag E; Mukadi YD; Colebunders R; Auld AF; Agolory S; Kaplan JE; Mulenga M; Kwesigabo GP; Wabwire-Mangen F; Bangsberg DR
AIDS; 2015 Jan; 29(3):361-71. PubMed ID: 25686684
[TBL] [Abstract][Full Text] [Related]
10. Durability of viral suppression with first-line antiretroviral therapy in patients with HIV in the UK: an observational cohort study.
O'Connor J; Smith C; Lampe FC; Johnson MA; Chadwick DR; Nelson M; Dunn D; Winston A; Post FA; Sabin C; Phillips AN;
Lancet HIV; 2017 Jul; 4(7):e295-e302. PubMed ID: 28479492
[TBL] [Abstract][Full Text] [Related]
11. Plasma HIV-1 RNA viral load rebound among people who inject drugs receiving antiretroviral therapy (ART) in a Canadian setting: an ethno-epidemiological study.
Small W; Milloy MJ; McNeil R; Maher L; Kerr T
AIDS Res Ther; 2016; 13():26. PubMed ID: 27462360
[TBL] [Abstract][Full Text] [Related]
12. Brief Report: Appraising Viral Load Thresholds and Adherence Support Recommendations in the World Health Organization Guidelines for Detection and Management of Virologic Failure.
McCluskey SM; Boum Y; Musinguzi N; Haberer JE; Martin JN; Hunt PW; Marconi VC; Bangsberg DR; Siedner MJ
J Acquir Immune Defic Syndr; 2017 Oct; 76(2):183-187. PubMed ID: 28628529
[TBL] [Abstract][Full Text] [Related]
13. Virological remission after antiretroviral therapy interruption in female African HIV seroconverters.
Gossez M; Martin GE; Pace M; Ramjee G; Premraj A; Kaleebu P; Rees H; Inshaw J; Stöhr W; Meyerowitz J; Hopkins E; Jones M; Hurst J; Porter K; Babiker A; Fidler S; Frater J;
AIDS; 2019 Feb; 33(2):185-197. PubMed ID: 30325764
[TBL] [Abstract][Full Text] [Related]
14. Non-uptake of viral load testing among people receiving HIV treatment in Gomba district, rural Uganda.
Nakalega R; Mukiza N; Kiwanuka G; Makanga-Kakumba R; Menge R; Kataike H; Maena J; Akello C; Atuhaire P; Matovu-Kiweewa F; Ndikuno-Kuteesa C; Debem H; Mujugira A
BMC Infect Dis; 2020 Oct; 20(1):727. PubMed ID: 33023498
[TBL] [Abstract][Full Text] [Related]
15. HIV virologic failure and its predictors among HIV-infected adults on antiretroviral therapy in the African Cohort Study.
Kiweewa F; Esber A; Musingye E; Reed D; Crowell TA; Cham F; Semwogerere M; Namagembe R; Nambuya A; Kafeero C; Tindikahwa A; Eller LA; Millard M; Gelderblom HC; Keshinro B; Adamu Y; Maswai J; Owuoth J; Sing'oei VC; Maganga L; Bahemana E; Khamadi S; Robb ML; Ake JA; Polyak CS; Kibuuka H
PLoS One; 2019; 14(2):e0211344. PubMed ID: 30721233
[TBL] [Abstract][Full Text] [Related]
16. A simple self-reported adherence tool as a predictor of viral rebound in people with viral suppression on antiretroviral therapy.
O'Connor JL; Gardner EM; Esser S; Mannheimer SB; Lifson AR; Telzak EE; Phillips AN;
HIV Med; 2016 Feb; 17(2):124-32. PubMed ID: 26186609
[TBL] [Abstract][Full Text] [Related]
17. Patterns of adherence to antiretroviral therapy and HIV drug resistance over time in the Stratall ANRS 12110/ESTHER trial in Cameroon.
Meresse M; March L; Kouanfack C; Bonono RC; Boyer S; Laborde-Balen G; Aghokeng A; Suzan-Monti M; Delaporte E; Spire B; Carrieri MP; Laurent C;
HIV Med; 2014 Sep; 15(8):478-87. PubMed ID: 24589279
[TBL] [Abstract][Full Text] [Related]
18. Effect of Anti-CD4 Antibody UB-421 on HIV-1 Rebound after Treatment Interruption.
Wang CY; Wong WW; Tsai HC; Chen YH; Kuo BS; Lynn S; Blazkova J; Clarridge KE; Su HW; Lin CY; Tseng FC; Lai A; Yang FH; Lin CH; Tseng W; Lin HY; Finstad CL; Wong-Staal F; Hanson CV; Chun TW; Liao MJ
N Engl J Med; 2019 Apr; 380(16):1535-1545. PubMed ID: 30995373
[TBL] [Abstract][Full Text] [Related]
19. Super learner analysis of real-time electronically monitored adherence to antiretroviral therapy under constrained optimization and comparison to non-differentiated care approaches for persons living with HIV in rural Uganda.
Benitez AE; Musinguzi N; Bangsberg DR; Bwana MB; Muzoora C; Hunt PW; Martin JN; Haberer JE; Petersen ML
J Int AIDS Soc; 2020 Mar; 23(3):e25467. PubMed ID: 32202067
[TBL] [Abstract][Full Text] [Related]
20. Immunovirological response to combined antiretroviral therapy and drug resistance patterns in children: 1- and 2-year outcomes in rural Uganda.
Ahoua L; Guenther G; Rouzioux C; Pinoges L; Anguzu P; Taburet AM; Balkan S; Olson DM; Olaro C; Pujades-Rodríguez M
BMC Pediatr; 2011 Jul; 11():67. PubMed ID: 21791095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
